Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2011-05-10
2011-05-10
Wilson, James O (Department: 1624)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C546S112000
Reexamination Certificate
active
07939544
ABSTRACT:
The present invention is directed to novel compounds of Formula (I)pharmaceutically acceptable salts thereof, pro-drugs thereof, biologically active metabolites thereof, isomers thereof or stereoisomers thereof wherein the variables are as defined herein. The compounds of Formula (I) are useful as chemokine receptor antagonists and as such would be useful in treating certain conditions and diseases, especially inflammatory conditions and diseases and proliferative disorders and conditions, for example, rheumatoid arthritis, osteoarthritis, multiple sclerosis and asthma.
REFERENCES:
patent: 2005/0192302 (2005-09-01), Xue et al.
patent: 2005/0267146 (2005-12-01), Xue et al.
patent: 2007/0032526 (2007-02-01), Carter et al.
patent: WO 89/10961 (1989-11-01), None
patent: WO 02/44181 (2002-06-01), None
patent: WO 2005/037779 (2005-04-01), None
Wolff, Manfred E., Burger's Medicinal Chemistry and Drug Discovery, Fifth Ed., vol. 1: Principles and Practice, John Wiley & Sons, 1995, 975.
Banker, Gilbert S. et al., Modem Pharmaceutics, Marcel Dekker, New York, 1996.
Ansell Graham K.
Ericsson Anna M.
George Dawn M.
Li Biqin
Wang Lu
Abbott Laboratories
Leeser Erich A
Parial Andrew M.
Wilson James O
LandOfFree
Octahydropentalene compounds as chemokine receptor antagonists does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Octahydropentalene compounds as chemokine receptor antagonists, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Octahydropentalene compounds as chemokine receptor antagonists will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2668379